Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2010 | 5 | 6 | 659-665

Article title

EMMPRIN and fascin expression in non-small cell lung carcinoma


Title variants

Languages of publication



Fascin and EMMPRIN (CD 147) have a demonstrated relationship with the invasion and progression of many tumors. The aim of this study was to analyze fascin and EMMPRIN expression in non-small cell lung carcinoma and their relationship with clinicopathologic features. Fascin and EMMPRIN expression levels were investigated via the immunohistochemistry of paraffin-embedded tissues of 64 patients with non-small cell lung carcinoma, including 46 squamous cell carcinoma and 18 adenocarcinoma patients. The patients were scored on the basis of staining extent and intensity, and were then assigned a combined score. Fascin expression was present in 44 of 46 (95.6%) patients with SCC and 16 of 18 (88.8%) patients with adenocarcinoma. There was a significant correlation between fascin expression and tumor stage in the SCC and adenocarcinoma groups. EMMPRIN expression was observed in all patients with SCC (46 of 46, 100%) and 16 of 18 (88.8%) patients with adenocarcinoma. There was significant correlation between EMMPRIN expression and both tumor stage and diameter in the SCC group, but not in the adenocarcinoma group. This study revealed that high levels of fascin and EMMPRIN expression may indicate the importance of their roles in the progression of non-small cell lung carcinoma and they could be used as prognostic marker for these tumors.











Physical description


1 - 12 - 2010
7 - 10 - 2010


  • Ondokuz Mayis University, 55139, Samsun, Turkey
  • Ondokuz Mayis University, 55139, Samsun, Turkey
  • Ondokuz Mayis University, 55139, Samsun, Turkey
  • Ondokuz Mayis University, 55139, Samsun, Turkey
  • Ondokuz Mayis University, 55139, Samsun, Turkey
  • Ondokuz Mayis University, 55139, Samsun, Turkey


  • [1] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J., Cancer statistics, CA Cancer J. Clin., 2008, 58, 71–96 http://dx.doi.org/10.3322/CA.2007.0010[Crossref]
  • [2] Husain A.N., The Lung, In: Kumar V., Abbas A.K., Fausto N., Aster J.C. eds. Robbins and Cotran Pathologic Basis of Disease. Eighth Edition, Philadelphia, Saunders Elsevier, 2010, 677–737
  • [3] Bepler G., Goodridge Carney D., Djulbegovic B., Clark R.A., Tockman M., A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest, Cancer Control 2003, 10, 306–14
  • [4] Al-Saad S., Al-Shibli K., Donnem T., Persson M., Bremnes R.M., Busund L.T., The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer, Br. J. Cancer, 2008, 99, 1476–83 http://dx.doi.org/10.1038/sj.bjc.6604713[Crossref]
  • [5] Nakashima M., Ohike N., Nagasaki K., Adachi M., Morohoshi T., Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma, J. Cancer Res. Clin. Oncol., 2004, 130, 475–9 http://dx.doi.org/10.1007/s00432-004-0571-x[Crossref]
  • [6] Perner S., Wagner P.L., Soltermann A., LaFargue C., Tischler V., Weir B.A., Weder W., Meyerson M., Giordano T.J., Moch H., Rubin M.A., TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival, J. Pathol., 2009, 217, 65–72 http://dx.doi.org/10.1002/path.2443
  • [7] Pelosi G., Barisella M., Pasini F., Leon M.E., Veronesi G., Spaggiari L., Fraggetta F., Iannucci A., Masullo M., Sonzogni A., Maffini F., Viale G., CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients, Mod. Pathol., 2004, 17, 711–21 http://dx.doi.org/10.1038/modpathol.3800110[Crossref]
  • [8] Hirabayashi H., Ohta M., Tanaka H., Sakaguchi M., Fujii Y., Miyoshi S., Matsuda H., Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53, J. Surg. Oncol., 2002, 81, 177–84 http://dx.doi.org/10.1002/jso.10176[Crossref]
  • [9] Sun J., Hemler M.E., Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions, Cancer Res., 2001, 61, 2276–81
  • [10] Muramatsu T., Miyauchi T., Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion, Histol. Histopathol, 2003, 18, 981–7
  • [11] Shapiro S.D., Matrix metalloproteinase degradation of extracellular matrix: biological consequences, Curr. Opin. Cell Biol., 1998, 10, 602–8 http://dx.doi.org/10.1016/S0955-0674(98)80035-5[Crossref]
  • [12] Chambers A.F., Matrisian L.M., Changing views of the role of matrix metalloproteinases in metastasis, J. Natl. Cancer Inst., 1997, 89, 1260–70 http://dx.doi.org/10.1093/jnci/89.17.1260[Crossref]
  • [13] Riethdorf S., Reimers N., Assmann V., Kornfeld J.W., Terracciano L., Sauter G., Pantel K., High incidence of EMMPRIN expression in human tumors, Int. J. Cancer 2006, 119, 1800–10 http://dx.doi.org/10.1002/ijc.22062[Crossref]
  • [14] Tsai W.C., Chao Y.C., Sheu L.F., Lin Y.F., Nieh S., Chen A., Yu C.P., Jin J.S., EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people, APMIS, 2007, 115, 929–38 http://dx.doi.org/10.1111/j.1600-0463.2007.apm_858.x[Crossref][WoS]
  • [15] Zheng H.C., Takahashi H., Murai Y., Cui Z.G., Nomoto K., Miwa S., Tsuneyama K., Takano Y., Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis, Br. J. Cancer, 2006, 95, 1371–8 http://dx.doi.org/10.1038/sj.bjc.6603425[Crossref]
  • [16] Tsai W.C., Chao Y.C., Lee W.H., Chen A., Sheu L.F., Jin J.S., Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters, Histopathology, 2006, 49, 388–95 http://dx.doi.org/10.1111/j.1365-2559.2006.02516.x[Crossref]
  • [17] Han Z.D., He H.C., Bi X.C., Qin W.J., Dai Q.S., Zou J., Ye Y.K., Liang Y.X., Zeng G.H., Zhu G., Chen Z.N., Zhong W.D., Expression and clinical significance of CD147 in genitourinary carcinomas, J. Surg. Res., 2008, (In press)
  • [18] De Arcangelis A., Georges-Labouesse E., Adams J.C., Expression of fascin-1, the gene encoding the actin-bundling protein fascin-1, during mouse embryogenesis, Gene Exp. Patt., 2004, 4, 637–43 http://dx.doi.org/10.1016/j.modgep.2004.04.012[Crossref]
  • [19] Hashimoto Y., Skacel M., Adams J.C., Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker?, Int. J. Biochem. Cell Biol., 2005, 37, 1787–804 http://dx.doi.org/10.1016/j.biocel.2005.05.004[Crossref]
  • [20] Kureishy N., Sapountzi V., Prag S., et al, Fascins, and their roles in cell structure and function, Bioessays, 2002, 24, 350–61 http://dx.doi.org/10.1002/bies.10070[Crossref]
  • [21] Pelosi G., Pastorino U., Pasini F., et al, Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer, Br. J. Cancer, 2003, 88, 537–47 http://dx.doi.org/10.1038/sj.bjc.6600731[Crossref]
  • [22] Peraud A., Mondal S., Hawkins C., et al, Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades, Brain Tumor Pathol., 2003, 20, 53–8 http://dx.doi.org/10.1007/BF02483447[Crossref]
  • [23] Rodriguez-Pinilla S.M., Sarrio D., Honrado E., et al, Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res, 2006, 12, 1533–39 http://dx.doi.org/10.1158/1078-0432.CCR-05-2281[Crossref]
  • [24] Tong G.X., Yee H., Chiriboga L., et al, Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder, Hum. Pathol., 2005, 36, 741–6 http://dx.doi.org/10.1016/j.humpath.2005.05.005
  • [25] Grothey A., Hashizume R., Sahin A.A., et al, Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer, Br. J. Cancer, 2000, 83, 870–73 http://dx.doi.org/10.1054/bjoc.2000.1395[Crossref]
  • [26] Hashimoto Y., Shimada Y., Kawamura J., et al, The prognostic relevance of fascin expression in human gastric carcinoma, Oncology, 2004, 67, 262–70 http://dx.doi.org/10.1159/000081327[Crossref]
  • [27] Pelosi G., Pastorino U., Pasini F., Maissoneuve P., Fraggetta F., Iannucci A., Sonzogni A., De Manzoni G., Terzi A., Durante E., Bresaola E., Pezzella F., Viale G., Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer, Br. J. Cancer, 2003, 88, 537–47 http://dx.doi.org/10.1038/sj.bjc.6600731[Crossref]
  • [28] Choi P.J., Yang D.K., Son C.H., Lee K.E., Lee J.I., Roh M.S., Fascin immunoreactivity for preoperatively predicting lymph node metastases in peripheral adenocarcinoma of the lung 3 cm or less in diameter, Eur. J. Cardiothorac Surg, 2006, 30, 538–42 http://dx.doi.org/10.1016/j.ejcts.2006.06.029[Crossref]
  • [29] Hakuma N., Betsuyaku T., Kinoshita I., Itoh T., Kaga K., Kondo S., Nishimura M., Dosaka-Akita H., High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters, Oncology, 2007, 72, 197–204 http://dx.doi.org/10.1159/000112826[WoS][Crossref]
  • [30] Sienel W., Polzer B., Elshawi K., Lindner M., Morresi-Hauf A., Vay C., Eder F., Passlick B., Klein CA., Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9, Mod. Pathol., 2008, 21, 1130–8 http://dx.doi.org/10.1038/modpathol.2008.102[Crossref]
  • [31] Travis W.D., Brambilla E., Muller-Hermelink K.H., Harris C.C., Pathology and genetics of tumours of the lung, pleura, thymus and heart, IARC Press, Lyon 2004, p. 9–124

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.